3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||g·mol−1 213.281|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Mechanism of action
Guanadrel is a postganglionic adrenergic blocking agent. Uptake of guanadrel and storage in sympathetic neurons occurs via the norepinephrine pump; guanadrel slowly displaces norepinephrine from its storage in nerve endings and thereby blocks the release of norepinephrine normally produced by nerve stimulation. The reduction in neurotransmitter release in response to sympathetic nerve stimulation, as a result of catecholamine depletion, leads to reduced arteriolar vasoconstriction, especially the reflex increase in sympathetic tone that occurs with a change in position. Guanadrel is rapidly and well absorbed from gastrointestinal tract.
Guanadrel can be synthesized when cyclohexanone undergoes ketalization by 3-chloro-1,2-propanediol, forming 2-chloromethyl-1,4-dioxyspiro[4,5]decane, which is further reacted with sodium phthalimide. After alkaline hydrazinolysis, the resulting phthalimide derivative is transformed into 2-aminomethyl-1,4-dioxyspiro[4,5]decane, which is reacted with S-methylthiourea, giving the desired guanadrel.
- Oren A, Rotmensch HH, Vlasses PH, et al. (1985). “A dose-titration trial of guanadrel as step-two therapy in essential hypertension”. J Clin Pharmacol. 25 (5): 343–6. doi:10.1002/j.1552-4604.1985.tb02852.x. PMID 4031111.[permanent dead link]
- Guanadrel, from Pharmacogenetics Knowledge Base
- M. I. Dunn and J. L. Dunlap (1981). “Guanadrel. A new antihypertensive drug”. JAMA. 245 (16): 1639–42. doi:10.1001/jama.1981.03310410017019. PMID 7206175.
- W.R. Hardie, J.E. Aaron, ‹See Tfd›FR 1522153 (1968)
- W.R. Hardie, J.E. Aaron, S. Afr. Pat. 67 06.328 (1968)
- J.E. Aaron, W.R. Hardie, U.S. Patent 3,547,951 (1970)